154 related articles for article (PubMed ID: 37210888)
1. Prospective quality of life outcomes for human papillomavirus associated oropharynx cancer patients after surgery alone.
Stephens EM; Plonowska-Hirschfeld K; Gulati A; Kansara S; Qualliotine J; Zelbolsky AL; van Zante A; Ha PK; Heaton CM; Ryan WR
Am J Otolaryngol; 2023; 44(4):103915. PubMed ID: 37210888
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life After Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharynx Cancer.
Silver JA; Bouganim N; Richardson K; Henry M; Mascarella MA; Ramirez-GarciaLuna J; Golabi N; Mlynarek AM; Zeitouni A; Hier MP; Caglar D; Esfahani K; Sadeghi N
JAMA Otolaryngol Head Neck Surg; 2024 Jan; 150(1):65-74. PubMed ID: 38060238
[TBL] [Abstract][Full Text] [Related]
3. Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer.
Xu MJ; Plonowska KA; Gurman ZR; Humphrey AK; Ha PK; Wang SJ; El-Sayed IH; Heaton CM; George JR; Yom SS; Algazi AP; Ryan WR
Laryngoscope; 2020 Feb; 130(2):E48-E56. PubMed ID: 30919470
[TBL] [Abstract][Full Text] [Related]
4. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma.
Plonowska-Hirschfeld KA; Gulati A; Stephens EM; Ochoa E; Xu MJ; Ha PK; Heaton CM; Yom SS; Chan JW; Algazi A; Kang H; Ryan WR
Laryngoscope; 2024 Apr; 134(4):1687-1695. PubMed ID: 37767815
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
Yin X; Shan C; Wang J; Zhang H
Oral Oncol; 2020 Apr; 103():104590. PubMed ID: 32050152
[TBL] [Abstract][Full Text] [Related]
6. A Descriptive Study of Quality of Life Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Diaconescu A; Silver JA; Subramaniam T; Sewitch MJ; Mascarella MA; Ramirez-Garcia Luna J; Golabi N; Richardson K; Bouganim N; Forghani R; Marcin Mlynarek A; Hier MP; Sadeghi N
J Otolaryngol Head Neck Surg; 2024; 53():19160216241248670. PubMed ID: 38888957
[TBL] [Abstract][Full Text] [Related]
7. Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer.
Scott SI; Kathrine Ø Madsen A; Rubek N; Charabi BW; Wessel I; Fredslund Hadjú S; Jensen CV; Stephen S; Patterson JM; Friborg J; Hutcheson KA; Kehlet H; von Buchwald C
Cancer Med; 2021 Jan; 10(2):483-495. PubMed ID: 33277795
[TBL] [Abstract][Full Text] [Related]
8. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
9. Risk of Pathologic Extranodal Extension and Other Adverse Features After Transoral Robotic Surgery in Patients With HPV-Positive Oropharynx Cancer.
Zebolsky AL; George E; Gulati A; Wai KC; Carpenter P; Van Zante A; Ha PK; Heaton CM; Ryan WR
JAMA Otolaryngol Head Neck Surg; 2021 Dec; 147(12):1080-1088. PubMed ID: 34673904
[TBL] [Abstract][Full Text] [Related]
10. Overall survival, disease-free survival and quality of life in patients affected by HPV mediated p16+ oropharyngeal squamous cell carcinoma treated with upfront trans-oral robotic surgery vs radiotherapy or chemoradiotherapy.
Fiacchini G; Picariello M; Dallan I; Tricò D; Casani AP; Amato F; Paiar F; Ursino S; Berrettini S; Bruschini L
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):1913-1921. PubMed ID: 38180604
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Mortality in HPV-Associated Oropharynx Carcinoma Treated With Surgery Alone.
Han M; Stanford-Moore GB; Larson AR; Schoppy DW; Cognetti DM; Joshi AS; Houlton JJ; Ryan WR
Laryngoscope; 2020 Jul; 130(7):E423-E435. PubMed ID: 31675132
[TBL] [Abstract][Full Text] [Related]
12. Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patients.
Ryan WR; Xu MJ; Ochoa E; Plonowska-Hirschfeld KA; Zebolsky AL; Ha PK; Bewley AF; Mallen-St Clair J; Joshi AS; Coffey CS; Faraji F; MacDonald BV; Houlton JJ; Gobillot TA; Curry JM; Philips R; Hackman TG; Richmon JD; Holcomb AJ; Coughlin AM; Panwar A; Smith RB; Herberg ME; Fakhry C; Cognetti DM
Cancer; 2021 Sep; 127(17):3092-3106. PubMed ID: 33957701
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality.
Maxwell JH; Mehta V; Wang H; Cunningham D; Duvvuri U; Kim S; Johnson JT; Ferris RL
Laryngoscope; 2014 Jul; 124(7):1592-7. PubMed ID: 24353066
[TBL] [Abstract][Full Text] [Related]
14. Neck scar perception after neck dissection in HPV-associated oropharyngeal squamous cell carcinoma.
Au VH; Miller LE; Mitchell MB; Larson AR; Lin DT; Feng AL; Richmon JD
Am J Otolaryngol; 2024; 45(1):104074. PubMed ID: 37865986
[TBL] [Abstract][Full Text] [Related]
15. Utilizing the AJCC 8
Kim SI; Lee JW; Eun YG; Lee YC
Anticancer Res; 2024 Apr; 44(4):1703-1710. PubMed ID: 38538003
[TBL] [Abstract][Full Text] [Related]
16. Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
Wang K; Amdur RJ; Mendenhall WM; Green R; Aumer S; Hackman TG; Zanation AM; Zevallos JP; Patel SN; Weissler MC; Chera BS
Oral Oncol; 2016 Jul; 58():21-6. PubMed ID: 27311398
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.
Pearlstein KA; Wang K; Amdur RJ; Shen CJ; Dagan R; Weiss J; Grilley-Olson JE; Zanation A; Hackman TG; Thorp BD; Blumberg JM; Patel S; Sheets N; Weissler MC; Mendenhall WM; Chera BS
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):646-653. PubMed ID: 30395903
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer.
Gulati A; Plonowska-Hirschfeld K; Stephens EM; Kansara S; Zebolsky AL; Ochoa E; Xu MJ; Ha PK; Heaton CM; Yom SS; Chan JW; Algazi AP; Kang H; Ryan WR
Clin Otolaryngol; 2023 Sep; 48(5):756-765. PubMed ID: 37212448
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor HPV DNA assessments after surgery for human papilloma virus-associated oropharynx carcinoma.
Souza SS; Stephens EM; Bourdillon AT; Bhethanabotla R; Farzal Z; Plonowska-Hirschfeld K; Qualliotine JR; Heaton CM; Ha PK; Ryan WR
Am J Otolaryngol; 2024; 45(2):104184. PubMed ID: 38101135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
